Insulin glargine compared to NPH among insulin-naïve, U.S. inner city, ethnic minority type 2 diabetic patients

Diabetes Research and Clinical Practice

Volumn 91, Issue 3, 2011, Pages 293-299

  Hsia, Stanley H ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Ethnicity; Glargine; Low income

Indexed keywords

GLITAZONE DERIVATIVE; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; BODY MASS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; UNITED STATES; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CIRCADIAN RHYTHM; CITIES; DIABETES MELLITUS, TYPE 2; ETHNIC GROUPS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, NPH; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MINORITY GROUPS; TREATMENT OUTCOME; WEIGHT GAIN; YOUNG ADULT;

EID: 79952360063     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.11.028     Document Type: Article

References (23)

1. American Diabetes Association. Diabetes statistics. Available at: [accessed 28.07.10]. http://www.diabetes.org/diabetes-basics/diabetes-statistics.
2. Rose D. Economic determinants and dietary consequences of food insecurity in the United States. J Nutr 1999, 129:517S-520S.
3. Alaimo K., Briefel R.R., Frongillo E.A., Olson C.M. Food insufficiency exists in the United States: results from the third National Health and Nutrition Examination Survey (NHANES III). Am J Public Health 1998, 88:419-426.
4. Pan C.Y., Sinnassamy P., Chung K.D., Kim K.W. Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Res Clin Pract 2007, 76:111-118.
5. Fritsche A., Schweitzer M.A., Haring H.U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003, 138:952-959.
6. Yki-Jarvinen H., Kauppinen-Makelin R., Tiikkainen M., Vahatalo M., Virtamo H., Nikkila K., et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006, 49:442-451.
7. Eliaschewitz F.G., Calvo C., Valbuena H., Ruiz M., Aschner P., Villena J., et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 2006, 37:495-501.
8. Riddle M.C., Rosenstock J., Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26:3080-3086.
9. Massi Benedetti M., Humburg E., Dressler A., Ziemen M. A one-year, randomised multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003, 35:189-196.
10. HOE 901/2004 Study Investigators Group Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type 2 diabetic patients. Diabetic Med 2003, 20:545-551.
11. Rosenstock J., Schwartz S.L., Clark C.M., Park G.D., Donley D.W., Edwards M.B. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001, 24:631-636.
12. Yki-Jarvinen H., Dressler A., Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000, 23:1130-1136. The HOE 901/3002 Study Group.
13. Wang X.L., Lu J.M., Pan C.Y., Mu Y.M., Dou J.T., Ba J.M., et al. Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system. Diabetes Res Clin Pract 2007, 76:30-36.
14. Bazzano L.A., Lee L.J., Shi L., Reynolds K., Jackson J.A., Fonseca V. Safety and efficacy of glargine compared with NPH insulin for the treatment of type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetic Med 2008, 25:924-932.
15. Bradley C., Plowright R., Stewart J., Valentine J., Witthaus E. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. Health Qual Life Outcomes 2007, 5:57.
16. Tran M.T., Navar M.D., Davidson M.B. Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes. Diabetes Care 2006, 29:1395-1396.
17. Rose D., Oliveira V. Nutrient intakes of individuals from food-insufficient households in the United States. Am J Public Health 1997, 87:1956-1961.
18. Feinberg E., Kavanagh P.L., Young R.L., Prudent N. Food insecurity and compensatory feeding practices among urban black families. Pediatrics 2008, 122:e854-e860.
19. Nelson K., Brown M.E., Lurie N. Hunger in an adult patient population. JAMA 1998, 279:1211-1214.
20. Levin P. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics. Diabetes Obes Metab 2008, 10(Suppl. 2):66-75.
21. Schoffski O., Breitscheidel L., Benter U., Dippel F.W., Muller M., Volk M., et al. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study. J Med Econ 2008, 11:695-712.
22. Cameron C.G., Bennett H.A. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009, 180:400-407.
23. Lee L.J., Yu A.P., Johnson S.J., Birnbaum H.G., Atanasov P., Buesching D.P., et al. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis. Diabetes Res Clin Pract 2010, 87:108-116.